Abstract | PURPOSE: EXPERIMENTAL DESIGN: RESULTS:
Axitinib monotherapy induced sustained growth stasis in PC-3 tumors in association with extensive apoptotic cell death. A substantial decrease in tumor vascular patency was observed, exemplified by a near complete loss of Hoechst 33342 perfusion and the absence of pimonidazole staining in the increasingly hypoxic tumors. Antitumor activity was significantly enhanced in both PC-3 and 9L tumors treated using an optimized schedule of sequential, intermittent axitinib- cyclophosphamide combination therapy despite a 40% to 70% decrease in tumor tissue uptake of 4-hydroxycyclophosphamide. CONCLUSIONS: In axitinib- cyclophosphamide combination therapy, enhanced anticancer activity can be achieved when the reduced tumor cell exposure to the cancer chemotherapeutic agent is compensated by antiangiogenesis-induced tumor cell starvation. This intrinsic antitumor effect was particularly evident in PC-3 tumor xenografts, where tumor blood flow deprivation dominates the overall therapeutic response.
|
Authors | Jie Ma, David J Waxman |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 15
Issue 2
Pg. 578-88
(Jan 15 2009)
ISSN: 1078-0432 [Print] United States |
PMID | 19147763
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Angiogenesis Inhibitors
- Benzimidazoles
- Imidazoles
- Indazoles
- 4-hydroxycyclophosphamide
- Cyclophosphamide
- Axitinib
- bisbenzimide ethoxide trihydrochloride
|
Topics |
- Angiogenesis Inhibitors
(pharmacology)
- Animals
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Axitinib
- Benzimidazoles
(pharmacology)
- Cell Line, Tumor
- Cyclophosphamide
(administration & dosage, analogs & derivatives, metabolism, pharmacology)
- Genes, Dominant
- Humans
- Imidazoles
(administration & dosage)
- Indazoles
(administration & dosage)
- Male
- Mice
- Mice, Inbred ICR
- Mice, SCID
- Neoplasm Transplantation
- Prostatic Neoplasms
(drug therapy)
|